Atypical Antiglomerular Basement Membrane Disease in a Pediatric Patient Successfully Treated with Rituximab

Figure 2

Degree of proteinuria and antiglomerular basement membrane (anti-GBM) antibody levels during the course of illness. Spot urine protein-to-creatinine ratio (solid line) and anti-GBM antibody levels (dotted line) are shown relative to the time of biopsy. Limit of detection for anti-GBM antibody levels is 1.0 AI, which has remained <1.0 AI since day 43. Limit of detection for urine protein-to-creatinine ratio is 0.19, which has remained between <0.19 and 0.25 since day 64. Data extend to day 334 at the latest follow-up. Length of treatment is indicated by black bars below the X-axis.